<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335202</url>
  </required_header>
  <id_info>
    <org_study_id>B495/16</org_study_id>
    <nct_id>NCT03335202</nct_id>
  </id_info>
  <brief_title>Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis</brief_title>
  <official_title>Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kiel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory und intestinal microbiome will bei analyzed during a period of 6 months. In a
      retrospective analysis it will be looked for correlations between microbiome and cf therapy
      (e.g. inhaled and systemic antibiotics, cftr modifiers, proton pump Inhibitors, enzymes,
      nutritional habits), clinical status and self reported outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DNA will be isolated from sputum, throat swabs and stool samples and used for the generation
      of microbial profiles. Both bacterial and fungal profiles will be analyzed by next generation
      sequencing.

      Clinical outcome parameters (lung function test, weight, calprotectin, elastase, blood
      parameters, self reported outcome) will be recorded and analyzed along with medication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory microbiome</measure>
    <time_frame>24 weeks</time_frame>
    <description>abundance [operational taxonomic units]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intestinal microbiome</measure>
    <time_frame>24 weeks</time_frame>
    <description>abundance [operational taxonomic units]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Exspiratory Volume FEV1 [%pred]</measure>
    <time_frame>24 weeks</time_frame>
    <description>performed by bodyplethmograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight (kg)</measure>
    <time_frame>24 weeks</time_frame>
    <description>for children, height (cm) is also recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life [score]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cystic Fibrosis Questionnaire Revised CFQ-R [score 0-100, higher scores indicating better Quality of Life]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life [score]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Kiel Questionnaire Kiel-Q [score 0-100, higher scores indicating hetter Quality of Life]</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>cf patients at the cf centre Kiel</arm_group_label>
    <description>microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>analysis of microbiome</intervention_name>
    <description>microbial profiling by next generation sequencing</description>
    <arm_group_label>cf patients at the cf centre Kiel</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum, throat swab and stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult cf patients treated in Adult Cystic Fibrosis Center, Klinik für Innere Medizin I,
        UKSH Kiel
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has confirmed diagnosis of cystic fibrosis (sweat chloride &gt;60mmol/l and/or 2
             mutations in the cftr gene known to cause cystic fibrosis)

          -  subject is able to perform informed consent

        Exclusion Criteria:

          -  inability to give informed consent

          -  antibiotic therapy in the last 4 weeks prior to study start (exception: long term
             azithromycin therapy, long term antistaphylococcal therapy, long term inhaled
             antibiotics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid CF Bobis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Innere Medizin I, UKSH Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid CF Bobis, MD</last_name>
    <phone>+49-1578-8209311</phone>
    <email>ingrid.bobis@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Franke, PhD</last_name>
    <phone>+49-431-500-15110</phone>
    <email>a.franke@mucosa.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Innere Medizin I, UKSH KIel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid CF Bobis, MD</last_name>
      <phone>+49-1578-8209311</phone>
      <email>ingrid.bobis@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Andre Franke, PhD</last_name>
      <phone>+49-431-500-15110</phone>
      <email>a.franke@mucosa.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Schreiber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Burkhard Bewig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Franke, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinna Bang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kiel</investigator_affiliation>
    <investigator_full_name>Ingrid Bobis</investigator_full_name>
    <investigator_title>Dr. med., Oberärztin für Pneumologie, Head of Adult CF Centre UKSH Kiel, Klinik für Innere Medizin I UKSH Kiel</investigator_title>
  </responsible_party>
  <keyword>respiratory and intestinal microbiome</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>cftr modifier</keyword>
  <keyword>diversity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

